The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback